Members of the European Parliament are heading to the Netherlands to see whether the European Medicines Agency’s relocation process is going according to plan. The move follows Italian criticisms that the Dutch provided “incomplete” information about their readiness to host the agency.
The European Parliament is to send a delegation to Amsterdam on a “fact-finding mission” to ascertain whether the European Medicines Agency’s relocation to the Dutch capital is proceeding “as planned and with no interruption.” The visit will be led by the parliament’s rapporteur for the relocation, Italian MEP Giovanni La Via.
The new seat of the agency has to be approved by the parliament, and the idea of the visit to...
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.
A potential MFN drug pricing policy in the US could also lead to a greater push for collaborative action in the EU, such as joint procurement among the member states, says one European industry expert.
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
FDA regulation was painted as an obstacle to US dominance in the cell and gene therapy space even as panelists at an agency event praised the Office of Therapeutic Products' track record under Nicole Verdun.
